Funds

Investment Objective

To deliver consistent positive returns through investments in private and publicly traded global growth and innovative biopharma companies.

Investment Strategy

Private Portfolio Company

The portfolio will focus on companies that are mid/late stage private. The companies may be preclinical or clinical development in nature. Board of Director observation or Board of Director representation may occur either via an employee of Gordon MD Global Investments LP or an appointed representative. Once the company becomes a publicly traded entity Board participation would end. Investment periods for the private investments may vary, with the majority held over a multi-year period.

Private & Public Portfolio Company

The private portfolio will focus on companies that are mid/late stage and may involve Board of Director representation. The publicly traded mandate will be long-biased and opportunistically short with a focus on highly liquid mega cap biopharmaceutical companies. The global public portfolio is expected to comprise approximately 15-20 long investments across the market cap spectrum, typically consisting of SMIDs (70-80%) and mega/large caps (20-30%). Most of the exposure will be in the U.S., Europe, and Japan. Investment periods for the public and private investments may vary, with the majority held over a multi-year period.

Investment Periods

While Investment periods for both the public and private investments may vary, we expect to hold the majority over multi-year periods.